1
|
Tanudji J, Kasai H, Okada M, Ogawa T, Aspera SM, Nakanishi H. 211At on gold nanoparticles for targeted radionuclide therapy application. Phys Chem Chem Phys 2024; 26:12915-12927. [PMID: 38629229 DOI: 10.1039/d3cp05326a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/02/2024]
Abstract
Targeted alpha therapy (TAT) is a methodology that is being developed as a promising cancer treatment using the α-particle decay of radionuclides. This technique involves the use of heavy radioactive elements being placed near the cancer target area to cause maximum damage to the cancer cells while minimizing the damage to healthy cells. Using gold nanoparticles (AuNPs) as carriers, a more effective therapy methodology may be realized. AuNPs can be good candidates for transporting these radionuclides to the vicinity of the cancer cells since they can be labeled not just with the radionuclides, but also a host of other proteins and ligands to target these cells and serve as additional treatment options. Research has shown that astatine and iodine are capable of adsorbing onto the surface of gold, creating a covalent bond that is quite stable for use in experiments. However, there are still many challenges that lie ahead in this area, whether they be theoretical, experimental, and even in real-life applications. This review will cover some of the major developments, as well as the current state of technology, and the problems that need to be tackled as this research topic moves along to maturity. The hope is that with more workers joining the field, we can make a positive impact on society, in addition to bringing improvement and more knowledge to science.
Collapse
Affiliation(s)
- Jeffrey Tanudji
- Department of Applied Physics, The University of Osaka, 2-1 Yamadaoka, Suita, Osaka 565-0871, Japan
| | - Hideaki Kasai
- Institute of Radiation Sciences, The University of Osaka, 1-1 Machikaneyama-cho, Toyonaka, Osaka 560-0043, Japan.
| | - Michio Okada
- Institute of Radiation Sciences, The University of Osaka, 1-1 Machikaneyama-cho, Toyonaka, Osaka 560-0043, Japan.
- Department of Chemistry, The University of Osaka, 1-1 Machikaneyama-cho, Toyonaka, Osaka 560-0043, Japan
| | - Tetsuo Ogawa
- Institute of Radiation Sciences, The University of Osaka, 1-1 Machikaneyama-cho, Toyonaka, Osaka 560-0043, Japan.
- Department of Physics, The University of Osaka, 1-1 Machikaneyama-cho, Toyonaka, Osaka 560-0043, Japan
| | - Susan M Aspera
- Research Initiative for Supra-Materials, Shinshu University, 4-17-1 Wakasato, Nagano, Nagano 380-8553, Japan
| | - Hiroshi Nakanishi
- National Institute of Technology, Akashi College, 679-3 Nishioka, Uozumi-cho, Akashi, Hyogo 674-8501, Japan
| |
Collapse
|
2
|
Juliyanto S, Dita Pertiwi L, Nurmanjaya A, Pujiyanto A, Setiawan H, Rindiyantono F, Abidin, Fikri A, Putra AR, Forentin AM, Susilo VY, Febrian MB, Ritawidya R, Yulizar Y. Phytosynthesis of gold-198 nanoparticles for a potential therapeutic radio-photothermal agent. Appl Radiat Isot 2024; 204:111141. [PMID: 38071856 DOI: 10.1016/j.apradiso.2023.111141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2023] [Revised: 11/22/2023] [Accepted: 12/04/2023] [Indexed: 12/31/2023]
Abstract
We produced spherical gold-198 nanoparticles with an average size of 41 nm, good stability, and high radiochemical purity for a promising single agent of radio-photothermal therapy using Curcuma longa rhizome extract as a reducing and capping agent. The combination of in vitro treatment using gold-198 nanoparticles and irradiation of 980 nm wavelength lasers with a power output of 2 W/cm2 induced hyperthermia temperature and exhibited enhancement of the percentage dead on MDA-MB-123 cancer cells compared to gold-198 nanoparticles alone.
Collapse
Affiliation(s)
- Sumandi Juliyanto
- Research Center for Radioisotope, Radiopharmaceutical, and Biodosimetry Technology, Research Organization for Nuclear Energy-National Research and Innovation Agency, BRIN, Puspiptek Area, South Tangerang, 15314, Indonesia; Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Indonesia, Depok, 16424, Indonesia.
| | - Ligwina Dita Pertiwi
- Research Center for Radioisotope, Radiopharmaceutical, and Biodosimetry Technology, Research Organization for Nuclear Energy-National Research and Innovation Agency, BRIN, Puspiptek Area, South Tangerang, 15314, Indonesia
| | - Ahid Nurmanjaya
- Research Center for Radioisotope, Radiopharmaceutical, and Biodosimetry Technology, Research Organization for Nuclear Energy-National Research and Innovation Agency, BRIN, Puspiptek Area, South Tangerang, 15314, Indonesia
| | - Anung Pujiyanto
- Research Center for Radioisotope, Radiopharmaceutical, and Biodosimetry Technology, Research Organization for Nuclear Energy-National Research and Innovation Agency, BRIN, Puspiptek Area, South Tangerang, 15314, Indonesia
| | - Herlan Setiawan
- Research Center for Radioisotope, Radiopharmaceutical, and Biodosimetry Technology, Research Organization for Nuclear Energy-National Research and Innovation Agency, BRIN, Puspiptek Area, South Tangerang, 15314, Indonesia
| | - Fernanto Rindiyantono
- Research Center for Radioisotope, Radiopharmaceutical, and Biodosimetry Technology, Research Organization for Nuclear Energy-National Research and Innovation Agency, BRIN, Puspiptek Area, South Tangerang, 15314, Indonesia
| | - Abidin
- Research Center for Radioisotope, Radiopharmaceutical, and Biodosimetry Technology, Research Organization for Nuclear Energy-National Research and Innovation Agency, BRIN, Puspiptek Area, South Tangerang, 15314, Indonesia
| | - Ahsanal Fikri
- Research Center for Radioisotope, Radiopharmaceutical, and Biodosimetry Technology, Research Organization for Nuclear Energy-National Research and Innovation Agency, BRIN, Puspiptek Area, South Tangerang, 15314, Indonesia; Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Indonesia, Depok, 16424, Indonesia
| | - Amal Rezka Putra
- Research Center for Radioisotope, Radiopharmaceutical, and Biodosimetry Technology, Research Organization for Nuclear Energy-National Research and Innovation Agency, BRIN, Puspiptek Area, South Tangerang, 15314, Indonesia
| | - Alfian Mahardika Forentin
- Research Center for Radioisotope, Radiopharmaceutical, and Biodosimetry Technology, Research Organization for Nuclear Energy-National Research and Innovation Agency, BRIN, Puspiptek Area, South Tangerang, 15314, Indonesia
| | - Veronika Yulianti Susilo
- Research Center for Radioisotope, Radiopharmaceutical, and Biodosimetry Technology, Research Organization for Nuclear Energy-National Research and Innovation Agency, BRIN, Puspiptek Area, South Tangerang, 15314, Indonesia
| | - Muhamad Basit Febrian
- Research Center for Radioisotope, Radiopharmaceutical, and Biodosimetry Technology, Research Organization for Nuclear Energy-National Research and Innovation Agency, BRIN, Puspiptek Area, South Tangerang, 15314, Indonesia
| | - Rien Ritawidya
- Research Center for Radioisotope, Radiopharmaceutical, and Biodosimetry Technology, Research Organization for Nuclear Energy-National Research and Innovation Agency, BRIN, Puspiptek Area, South Tangerang, 15314, Indonesia
| | - Yoki Yulizar
- Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Indonesia, Depok, 16424, Indonesia
| |
Collapse
|
3
|
Souza BNRF, Ribeiro ERFR, da Silva de Barros AO, Pijeira MSO, Kenup-Hernandes HO, Ricci-Junior E, Diniz Filho JFS, dos Santos CC, Alencar LMR, Attia MF, Gemini-Piperni S, Santos-Oliveira R. Nanomicelles of Radium Dichloride [ 223Ra]RaCl 2 Co-Loaded with Radioactive Gold [ 198Au]Au Nanoparticles for Targeted Alpha-Beta Radionuclide Therapy of Osteosarcoma. Polymers (Basel) 2022; 14:polym14071405. [PMID: 35406278 PMCID: PMC9002948 DOI: 10.3390/polym14071405] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2022] [Revised: 03/24/2022] [Accepted: 03/26/2022] [Indexed: 12/20/2022] Open
Abstract
Alpha and beta particulate radiation are used for non-treated neoplasia, due to their ability to reach and remain in tumor sites. Radium-223 (223Ra), an alpha emitter, promotes localized cytotoxic effects, while radioactive gold (198Au), beta-type energy, reduces radiation in the surrounding tissues. Nanotechnology, including several radioactive nanoparticles, can be safely and effectively used in cancer treatment. In this context, this study aims to analyze the antitumoral effects of [223Ra]Ra nanomicelles co-loaded with radioactive gold nanoparticles ([198Au]AuNPs). For this, we synthesize and characterize nanomicelles, as well as analyze some parameters, such as particle size, radioactivity emission, dynamic light scattering, and microscopic atomic force. [223Ra]Ra nanomicelles co-loaded with [198Au]AuNPs, with simultaneous alpha and beta emission, showed no instability, a mean particle size of 296 nm, and a PDI of 0.201 (±0.096). Furthermore, nanomicelles were tested in an in vitro cytotoxicity assay. We observed a significant increase in tumor cell death using combined alpha and beta therapy in the same formulation, compared with these components used alone. Together, these results show, for the first time, an efficient association between alpha and beta therapies, which could become a promising tool in the control of tumor progression.
Collapse
Affiliation(s)
- Bárbara Nayane Rosário Fernandes Souza
- Argonauta Nuclear Reactor Center, Nuclear Engineering Institute, Brazilian Nuclear Energy Commission, Rio de Janeiro 21941-906, Brazil; (B.N.R.F.S.); (E.R.F.R.R.); (A.O.d.S.d.B.); (M.S.O.P.)
| | - Elisabete Regina Fernandes Ramos Ribeiro
- Argonauta Nuclear Reactor Center, Nuclear Engineering Institute, Brazilian Nuclear Energy Commission, Rio de Janeiro 21941-906, Brazil; (B.N.R.F.S.); (E.R.F.R.R.); (A.O.d.S.d.B.); (M.S.O.P.)
| | - Aline Oliveira da Silva de Barros
- Argonauta Nuclear Reactor Center, Nuclear Engineering Institute, Brazilian Nuclear Energy Commission, Rio de Janeiro 21941-906, Brazil; (B.N.R.F.S.); (E.R.F.R.R.); (A.O.d.S.d.B.); (M.S.O.P.)
| | - Martha Sahylí Ortega Pijeira
- Argonauta Nuclear Reactor Center, Nuclear Engineering Institute, Brazilian Nuclear Energy Commission, Rio de Janeiro 21941-906, Brazil; (B.N.R.F.S.); (E.R.F.R.R.); (A.O.d.S.d.B.); (M.S.O.P.)
| | - Hericka Oliveira Kenup-Hernandes
- Laboratory of Nanoradiopharmaceuticals and Synthesis of Novel Radiopharmaceuticals, Nuclear Engineering Institute, Brazilian Nuclear Energy Commission, Rio de Janeiro 21941-906, Brazil;
| | - Eduardo Ricci-Junior
- DEFARMED Laboratory, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-900, Brazil;
| | - Joel Félix Silva Diniz Filho
- Laboratory of Biophysics and Nanosystems, Department of Physics, Federal University of Maranhão, São Luís 65080-805, Brazil; (J.F.S.D.F.); (C.C.d.S.); (L.M.R.A.)
| | - Clenilton Costa dos Santos
- Laboratory of Biophysics and Nanosystems, Department of Physics, Federal University of Maranhão, São Luís 65080-805, Brazil; (J.F.S.D.F.); (C.C.d.S.); (L.M.R.A.)
| | - Luciana Magalhães Rebelo Alencar
- Laboratory of Biophysics and Nanosystems, Department of Physics, Federal University of Maranhão, São Luís 65080-805, Brazil; (J.F.S.D.F.); (C.C.d.S.); (L.M.R.A.)
| | - Mohamed F. Attia
- Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA;
| | - Sara Gemini-Piperni
- Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, Brazil;
| | - Ralph Santos-Oliveira
- Argonauta Nuclear Reactor Center, Nuclear Engineering Institute, Brazilian Nuclear Energy Commission, Rio de Janeiro 21941-906, Brazil; (B.N.R.F.S.); (E.R.F.R.R.); (A.O.d.S.d.B.); (M.S.O.P.)
- Laboratory of Radiopharmacy and Nanoradiopharmaceuticals, Zona Oeste State University, Rio de Janeiro 23070-200, Brazil
- Correspondence:
| |
Collapse
|
4
|
Green nanotechnology—An innovative pathway towards biocompatible and medically relevant gold nanoparticles. J Drug Deliv Sci Technol 2022. [DOI: 10.1016/j.jddst.2022.103256] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
5
|
Seniwal B, Thipe VC, Singh S, Fonseca TCF, Freitas de Freitas L. Recent Advances in Brachytherapy Using Radioactive Nanoparticles: An Alternative to Seed-Based Brachytherapy. Front Oncol 2021; 11:766407. [PMID: 34900715 PMCID: PMC8651618 DOI: 10.3389/fonc.2021.766407] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2021] [Accepted: 10/29/2021] [Indexed: 12/24/2022] Open
Abstract
Interstitial brachytherapy (BT) is generally used for the treatment of well-confined solid tumors. One example of this is in the treatment of prostate tumors by permanent placement of radioactive seeds within the prostate gland, where low doses of radiation are delivered for several months. However, successful implementation of this technique is hampered due to several posttreatment adverse effects or symptoms and operational and logistical complications associated with it. Recently, with the advancements in nanotechnology, radioactive nanoparticles (radio-NPs) functionalized with tumor-specific biomolecules, injected intratumorally, have been reported as an alternative to seed-based BT. Successful treatment of solid tumors using radio-NPs has been reported in several preclinical studies, on both mice and canine models. In this article, we review the recent advancements in the synthesis and use of radio-NPs as a substitute to seed-based BT. Here, we discuss the limitations of current seed-based BT and advantages of radio-NPs for BT applications. Recent progress on the types of radio-NPs, their features, synthesis methods, and delivery techniques are discussed. The last part of the review focuses on the currently used dosimetry protocols and studies on the dosimetry of nanobrachytherapy applications using radio-NPs. The current challenges and future research directions on the role of radio-NPs in BT treatments are also discussed.
Collapse
Affiliation(s)
- Baljeet Seniwal
- Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval (CR-CHU de Québec), Axe Médecine Régénératrice, Québec, QC, Canada
| | - Velaphi C Thipe
- Instituto de Pesquisas Energéticas e Nucleares, Comissão Nacional de Energia Nuclear (IPEN-CNEN), Cidade Universitária, São Paulo, Brazil.,Department of Radiology, Institute of Green Nanotechnology, School of Medicine, University of Missouri, Columbia, MO, United States
| | - Sukhvir Singh
- Institute of Nuclear Medicine and Allied Sciences, Defence Research and Development Organisation, Delhi, India
| | - Telma C F Fonseca
- Departamento de Engenharia Nuclear-Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
| | - Lucas Freitas de Freitas
- Instituto de Pesquisas Energéticas e Nucleares, Comissão Nacional de Energia Nuclear (IPEN-CNEN), Cidade Universitária, São Paulo, Brazil
| |
Collapse
|
6
|
Wang Z, Ye M, Ma D, Shen J, Fang F. Engineering of 177Lu-labeled gold encapsulated into dendrimeric nanomaterials for the treatment of lung cancer. JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION 2021; 33:197-211. [PMID: 34686102 DOI: 10.1080/09205063.2021.1982446] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
As a novel type of theranostic radioactive agents, 177Lu-labeled nanomaterials conjugated to macromolecules have been described. The study aimed to fabricate PAMAM-G4-(177Lu-dendrimer)-bombesin-folate in the dendrimeric cavity, assess the radiopharmaceutical ability for specifically targeted radiotherapy and simultaneously detects gastrin-releasing peptide receptors (GRPR) and folate receptors (FRs) overexpressed in lung carcinoma cells, respectively. In an aqueous-basic media, p-SCN-benzyl-DOTA was conjugated to the dendrimer. This dendrimer was formed by activating the carboxylic acid groups of DOTA-folic acid and bombesin with HATU and conjugating them to develop the dendrimer. As part of this process, the conjugate was combined with 1% HAuCl4, added NaBH4 and filtered by ultrafiltration. Infrared, UV-Vis, TEM analysis, dynamic light scattering (DLS), and fluorescence spectroscopy were employed to observe the composition of the fabricated sample. Radio-labeled 177LuCl3 was used to label the conjugate, which was then evaluated using the radio-HPLC method. Findings demonstrated dendrimeric functionalization with remarkable radiochemical composition purity up to >96%. Because of fluorescence studies, it was determined that the occurrence of AuNMs in the dendrimeric cavities gives beneficial photo-physical characteristics to the radiopharmaceutical for bio-imaging. HEL-299 lung cancer cells exhibited a selective absorption of the drug (%). It might be helpful as nuclear and optical imaging agents for lung cancers that overexpress FRs and GRPR and as a specific target for radiation therapy if combined with folate-bombesin.
Collapse
Affiliation(s)
- Zheng Wang
- Department of Cardiothoracic Surgery, Taizhou Hospital of Zhejiang Province, Taizhou, China
| | - Minhua Ye
- Department of Cardiothoracic Surgery, Taizhou Hospital of Zhejiang Province, Taizhou, China
| | - Dehua Ma
- Department of Cardiothoracic Surgery, Taizhou Hospital of Zhejiang Province, Taizhou, China
| | - Jianfei Shen
- Department of Cardiothoracic Surgery, Taizhou Hospital of Zhejiang Province, Taizhou, China
| | - Fang Fang
- Operating Room, Taizhou Hospital of Zhejiang Province, Taizhou, China
| |
Collapse
|